SummaryRMgm-5561
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene tagging |
Reference (PubMed-PMID number) | Not published (yet) |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | RMgm-5555 |
Other information parent line | This mutant (RMgm-5555) expresses (a flag-tagged) CAS9 (spCAS9) under control of the strong and constitutive hsp70 promoter. The mutant does not contain a drug-selectable marker. |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Jonsdottir TK, Bushell ESC |
Name Group/Department | The Laboratory for Molecular Infection Medicine Sweden |
Name Institute | Umeå University |
City | Umeå |
Country | Sweden |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-5561 |
Principal name | PBANKA_PBANKA_1451000-3xcMyc |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | No |
top of page | |
Phenotype | |
Asexual blood stage | The mutant expresses a C-terminal 3x-cMyc-tagged version of PBANKA_PBANKA_1451000. The 3x-cMyc tag was introduced into the 3’ of PBANKA_1451000 of the background line RMgm-5555. The Cas9 expressed from the genome in the PbCas9 background line (RMgm-5555) facilitated integration of the 3x-cMyc tag using the CRISPR-Cas9 P. berghei High-Throughput strategy (PbHiT). The pPbHiT vector contains the gRNA barcode, 100 bp homology arms and two guides per gene. The tagged-gene contains a 3'-UTR regions of hsp70 (PBANKA_0711900). The expression of the protein was confirmed by Western blot analysis. |
Gametocyte/Gamete | Not tested |
Fertilization and ookinete | Not tested |
Oocyst | Not tested |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation PbHiT facilitates pooled transfection CRISPR screens in P. berghei |
top of page | |||||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1451000 | ||||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1236300 | ||||||||||||||||||||||||||
Gene product | conserved Plasmodium protein, unknown function | ||||||||||||||||||||||||||
Gene product: Alternative name | |||||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||||
Name of the tag | 3xcMyc | ||||||||||||||||||||||||||
Details of tagging | C-terminal | ||||||||||||||||||||||||||
Additional remarks: tagging | |||||||||||||||||||||||||||
Commercial source of tag-antibodies | |||||||||||||||||||||||||||
Type of plasmid/construct | CRISPR/Cas9 construct: integration through double strand break repair | ||||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||||
Additional remarks genetic modification | To generate a CRISPR-Cas9 system specifically adapted for P. berghei we modified the P. yoelii pYCm and pYCs plasmids (kind gift from Jing Yuan) by changing the P. yoelii U6 promoter (PyU6) that drives gRNA expression, for the P. berghei U6 promoter (PbU6; PBANKA_1354380). To this end, the PbU6 sequence was amplified from P. berghei ANKA cl15cy1 genomic DNA and cloned into the pYCs and pYCm plasmids following digestion with KasI and StuI (NEB), using the NEBuilder HiFi DNA reaction master mix. The resultant vectors were named pPbU6-hdhfr/yfcu-Cas9 (addgene ID 216423, derived from pYCm and containing the coding sequence for spCas9 nuclease) and pPbU6-hdhfr/yfcu (Addgene #216422, derived from pYCs). Both vectors contain the dual selection marker hdhfr/yfcu for positive selection with pyrimethamine and negative selection using 5-fluorocytosine (5-FC). To adapt this system for ease of cloning and pooled transfections, we generated a vector using the pPbU6-hdhfr/yfcu backbone in which the original gRNA scaffold sequence was replaced with a synthetic modular fragment carrying the following features: BsmBI/PstI/3x-cMyc/SalI/NotI/stop codon (TAG)/hsp70 3’UTR/AatII (ordered from GeneWiz-Azenta). The pPbU6-hdhfr/yfcu plasmid and the synthetic fragment were digested with BsmBI and AatII (NEB) and ligated into the vector with T4 ligase (NEB). The multiple cloning sites allow adding new or replacing all features. The resulting plasmid was named pPbU6-hdhfr/yfcu-HiT (Addgene #216421), referred to as pPbHiT. Vectors to target specific genes using pPbU6-hdhfr/yfcu were generated by first cloning the gRNAs into BsmBI-digested vectors. To this end, two single-stranded oligonucleotides (Integrated DNA Technologies, IDT) were designed containing the guide sequence fused to a 4-nucleotide sequence (TATT for the forward guide and AAAC for the reverse guide) corresponding to the overhangs generated when digesting the vectors with BsmBI. Single-stranded oligonucleotides were mixed in a 1:1 ratio, phosphorylated using the T4 polynucleotide kinase enzyme (NEB), and annealed by incubating at 95 °C for 5 min followed by a temperature ramp of -5 °C every minute, until reaching 25 °C. A 1:200 dilution of the double-stranded gRNA was ligated into BsmBI-digested plasmids using T4 ligase (NEB). One μL of the ligated vector was then transformed into chemically competent XL Gold E. coli (Agilent Technologies). Integration was determined by colony PCR using the gRNA forward oligonucleotide and the generic primer gRNAseq_R. The HDR templates were synthesised by GeneWiz-Azenta. To generate tagging vectors, the homology arms were designed flanking the cut-site of the gRNA, which was placed in the 3’ end of the coding sequence. Furthermore, the area containing the gRNA target sequence was recodonised to avoid successive cutting of the edited locus, and the desired epitope tag was added to the repair template. The HDR template was provided either in the same plasmid that carried the gRNA (one-plasmid approach), or as a PCR product (PCR-template approach). For the one-plasmid approach, the gene-specific homology repair template was ligated into plasmids carrying the corresponding gRNA using HindIII. For the PCR-template approach, the HDR template was amplified by PCR and the amplicon was incubated with DpnI or gel extracted. For rap2/3 only one guide was used per transfection but for sdg, piesp1 and mahrp1a two guides were mixed together with PCR-template prior to transfection and recodonised area in the HDR template covered the region of both gRNAs. The pPbHiT vectors to either knock out or tag target genes were designed with 50 or 100 bp homology arms, and the gRNAs were located in the region between the two homology arms, which results in the removal of the target site after recombination has occurred. For pPbHiT tagging vectors, the 5’ homology arm (HR1) is located at the end of the coding sequence and comprises the region immediately upstream of the stop codon without including it, whereas the 3’ homology arm (HR2) starts after the Cas9 cut site, 6 bp downstream of the gRNA protospacer adjacent motif (PAM) site. Guides within 50 bp from the end of the coding sequence are prioritised for tagging vectors to maximise editing efficiency. For pPbHiT knockout vectors, the HR1 is located in the 5’ UTR of the target gene immediately before the ATG codon, and the HR2 is designed in the 3’ UTR of the target gene just after the stop codon. All gene-specific elements and the generic gRNA scaffold were synthesised as a single synthetic fragment (Genewiz-Azenta) according to the following structure: BbsI/gRNA/Scaffold/HR2/AvrII/HR1/PstI for cloning into pPbHiT. If any of the cut sites were present in the sequence of the HR, the nucleotides were modified by introducing a silent mutation to remove the enzyme recognition site. The synthetic constructs were then ligated into the pPbHiT vector using the BbsI and PstI cloning sites. This places gRNA expression under the PbU6 promoter of the pPbHiT vector, and for tagging vectors the HR1 (corresponds to the 3’ end of the coding sequence) in-frame with the 3x-cMyc tag followed by the hsp70 3’UTR. Ligations were transformed into XL Gold E. coli as above and colonies were screened to check the presence of the insert by colony PCR using PbU6prom_F and hsp70UTR_R primers, except for the pooled vectors which were screened by NGS. The final pPbHiT vectors were linearised using the AvrII restriction enzyme prior to transfection. | ||||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
top of page |